PIK3CA and cancer: This pathway is up-regulated in cancer cells as a result of a variety of genetic alterations including over-expression of or activating mutations in receptor tyrosine kinases (e.g. ERBB2 or MET), activating mutations in PI3K subunits, loss or promoter methylation of PTEN and over-expression of or mutations in the AKTs [1].